RxDoctor Payments Data

Brittany Goss, DO

Rheumatology · Napa, CANPI 1093911356

Payments from drug & device makers

$48,205in general payments, 2019–2025

Across 463 payments — averaging $104.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Enterprises LLC$21K
  • Bristol Myers Squibb$15K
  • Amgen$5K
  • Biogen$2K
  • AbbVie$1K
  • Novartis$914
  • plus $4K from 18 others

What the payments were for

  • Consulting fees$5,93312%
  • Speaking & faculty fees$25,77753%
  • Travel & lodging$7,77816%
  • Food & beverage$8,52718%
  • Education$1910%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,205 in reported general payments places this provider in the 80th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$28,041
Medicare patients
153
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin13$959,232
StelaraUstekinumab18$419,576
Cosentyx Sensoready (2 Pens)Secukinumab41$358,048
OtezlaApremilast43$201,701
Xeljanz XrTofacitinib Citrate33$193,036
Taltz AutoinjectorIxekizumab21$161,265
Taltz Autoinjector (2 Pack)Ixekizumab11$149,527
EnbrelEtanercept15$141,608
RinvoqUpadacitinib20$123,592
Enbrel SureclickEtanercept16$111,052
RemicadeInfliximab11$68,654
SimponiGolimumab11$67,990
BenlystaBelimumab23$66,396
XolairOmalizumab12$34,744
Hydroxychloroquine Sulfate360$17,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mallinckrodt Hospital Products Inc.Acthar$600$959,23213 claims
Johnson & JohnsonStelara, Remicade, Simponi$233$556,22040 claims
AmgenOtezla, Enbrel$4,937$343,30958 claims
AbbVieRinvoq$1,047$123,59220 claims
GSKBenlysta$309$66,39623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 808 rheumatology providers in California.

Other rheumatology in Napa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →